BR112022018527A2 - Receptores construídos para coronavírus e seus usos - Google Patents

Receptores construídos para coronavírus e seus usos

Info

Publication number
BR112022018527A2
BR112022018527A2 BR112022018527A BR112022018527A BR112022018527A2 BR 112022018527 A2 BR112022018527 A2 BR 112022018527A2 BR 112022018527 A BR112022018527 A BR 112022018527A BR 112022018527 A BR112022018527 A BR 112022018527A BR 112022018527 A2 BR112022018527 A2 BR 112022018527A2
Authority
BR
Brazil
Prior art keywords
ace2
modified
cov
polypeptides
corona virus
Prior art date
Application number
BR112022018527A
Other languages
English (en)
Portuguese (pt)
Inventor
Procko Erik
Malik Asrar
Rehman Jalees
Zhang Lianghui
Xiong Shiqin
Original Assignee
Univ Illinois
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Illinois filed Critical Univ Illinois
Publication of BR112022018527A2 publication Critical patent/BR112022018527A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/485—Exopeptidases (3.4.11-3.4.19)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/17—Metallocarboxypeptidases (3.4.17)
    • C12Y304/17023—Angiotensin-converting enzyme 2 (3.4.17.23)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/165—Coronaviridae, e.g. avian infectious bronchitis virus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
BR112022018527A 2020-03-16 2021-03-16 Receptores construídos para coronavírus e seus usos BR112022018527A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202062989976P 2020-03-16 2020-03-16
US202063022151P 2020-05-08 2020-05-08
US202063042907P 2020-06-23 2020-06-23
US202063089895P 2020-10-09 2020-10-09
PCT/US2021/022611 WO2021188576A1 (en) 2020-03-16 2021-03-16 Modified angiotensin-converting enzyme 2 (ace2) and use thereof

Publications (1)

Publication Number Publication Date
BR112022018527A2 true BR112022018527A2 (pt) 2022-10-25

Family

ID=75439530

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022018527A BR112022018527A2 (pt) 2020-03-16 2021-03-16 Receptores construídos para coronavírus e seus usos

Country Status (8)

Country Link
US (1) US20230193235A1 (https=)
EP (1) EP4121170A1 (https=)
JP (1) JP2023518038A (https=)
KR (1) KR20220154796A (https=)
AU (1) AU2021239879A1 (https=)
BR (1) BR112022018527A2 (https=)
CA (1) CA3174683A1 (https=)
WO (1) WO2021188576A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116057176A (zh) * 2020-03-21 2023-05-02 赖瑞克斯生物科技公司 Ace2和补体途径的双特异性和三特异性功能分子及其用途
EP3884957A1 (en) * 2020-03-26 2021-09-29 The University of British Columbia Methods for treatment of virus and methods for screening of anti-virus reagent using organoids
US20230257726A1 (en) * 2020-05-11 2023-08-17 Chan Zuckerberg Biohub, Inc. Ace2 compositions and methods
IL276627A (en) * 2020-08-10 2022-03-01 Yeda Res & Dev Compositions for diagnosis and treatment of coronavirus infections
CN117120621A (zh) * 2020-11-12 2023-11-24 上海科技大学 提高效率和准确性的基因组编辑
JP2024540722A (ja) * 2021-11-01 2024-11-01 エージェンシー フォー サイエンス，テクノロジー アンド リサーチ 変異型アンジオテンシン変換酵素２（ａｃｅ２）を含む組換え／融合ポリペプチド
WO2023081958A1 (en) * 2021-11-11 2023-05-19 The Macfarlane Burnet Institute For Medical Research And Public Health Ltd Antiviral agent comprising a cellular entry receptor and fc region component
CN114606219B (zh) * 2022-04-01 2023-10-31 北京大学 一种冠状病毒中和效应蛋白及其应用
EP4507787A1 (en) * 2022-04-13 2025-02-19 Paradigm Immunotherapeutics, Inc. Methods of preventing or treating infection by respiratory viruses including sars-cov-2
CN117304317B (zh) * 2022-06-28 2024-08-02 四川大学 Ace2受体特异性结合肽及其应用
EP4386084A1 (en) * 2022-12-14 2024-06-19 Formycon AG Improved ace2 fusion proteins
WO2024215776A1 (en) * 2023-04-10 2024-10-17 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Recombinant ace2 polypeptide and uses thereof
KR20240177843A (ko) * 2023-06-20 2024-12-30 주식회사 엔큐라젠 SARS-CoV-2스파이크 단백질에 특이적으로 결합하는 펩타이드 및 이의 용도
CN117447609A (zh) * 2023-10-25 2024-01-26 山西锦波生物医药股份有限公司 灭活冠状病毒的融合蛋白及其应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1515752E (pt) * 2002-06-19 2009-03-05 Univ Health Network Activação de ace2 para o tratamento de doença cardíaca, pulmonar e renal e de hipertensão
AU2013216910A1 (en) * 2012-02-10 2014-08-28 Tarix Pharmaceuticals Ltd. Compositions and methods for treatment of peripheral vascular disease

Also Published As

Publication number Publication date
EP4121170A1 (en) 2023-01-25
JP2023518038A (ja) 2023-04-27
AU2021239879A1 (en) 2022-09-29
WO2021188576A1 (en) 2021-09-23
US20230193235A1 (en) 2023-06-22
CA3174683A1 (en) 2021-09-23
KR20220154796A (ko) 2022-11-22

Similar Documents

Publication Publication Date Title
BR112022018527A2 (pt) Receptores construídos para coronavírus e seus usos
ZA202213710B (en) Anti-sars-cov-2 infection protein and vaccine
BR112022013756A2 (pt) Anticorpos anti-trem2 e métodos de uso dos mesmos
Wroblewski et al. Different coupling of excitatory amino acid receptors with Ca2+ channels in primary cultures of cerebellar granule cells
BR0209689A (pt) Uso de fragmento de hmg como agente anti-inflamatório
Ichikawa et al. VR1-, VRL-1-and P2X3 receptor-immunoreactive innervation of the rat temporomandibular joint
NO20055525L (no) Vevsbeskyttende cytokinreseptorkompleks, assay for identifisering av vevsbeskyttende forbindelser og anvendelser derav
PT835266E (pt) Superantigenios modificados / quimericos e seu uso
BR112022003617A2 (pt) Métodos e composições para a modificação e distribuição de linfócitos
BR0211915A (pt) Execução de aplicação habilitada para teste
NO20056048L (no) Pan-Kirk2dl nk-receptor antibodies and their use in diagnostik and therapy
MXPA03010062A (es) Funcionalidad i de la proteina de canola aislada.
BR9911621A (pt) Bifenil sulfonamidas como antagonista duplos de receptor de angiotensina endotelina
CL2008002092A1 (es) Conjugado que contiene dos o mas peptidos antifusogenicos y un anticuerpo anti-cd-4; metodo de produccion; composicion farmaceutica que lo comprende; polipeptidos antifusogenicos y uso del conjugado para tratar infecciones viricas.
BR112022019542A2 (pt) Máscara facial antipatogênica
BR9910359A (pt) Proteìna hìbrida para inibição de desgranulação de mastócitos e seu uso
BRPI0410694A (pt) compostos de piperazina tetra e penta-substituìdos e de anel derivado de piperazina
BR112023025403A2 (pt) Composto heterocíclico bifuncional tendo função de degradação de btk por meio da via ubiquitina proteassoma e uso do mesmo
BR112022012205A2 (pt) Compostos ativos para receptores nucleares
WO2022226423A3 (en) Therapeutic interfering particles for corona virus
Mann et al. 1α, 25‐dihydroxyvitamin D3 acts via transforming growth factor‐β to up‐regulate expression of immunosuppressive CD73 on human CD4+ Foxp3–T cells
BR112022024262A2 (pt) Métodos de tratamento de nefropatia por iga com um anticorpo de ligação a april
BR112022022353A2 (pt) Composições e métodos para reprogramação de tcr usando proteínas de fusão específicas de cd70
BR112021024233A2 (pt) Implante para fixar um tendão ou um ligamento a um tecido duro compreendendo um eixo, primeiros pilares para entrar em contato com um tecido duro, e segundos pilares para entrar em contato com um tendão ou um ligamento
NO973026L (no) Nye monoklonale antistoffer med virksom inhibitorisk aktivitet mot type II-fosfolipase A2 og proteiner omfattende en del derav